Boston Scientific Corp. on Tuesday announced plans for a $210 million acquisition that would broaden the medical technology company's line of products for diagnosis and treatment of gastrointestinal conditions like colon cancer.

Massachusetts-based Boston Scientific, which derives two-thirds of its revenue from divisions based in Minnesota, said it will acquire all the stock of EndoChoice Holdings in Alpharetta, Ga. The deal is expected to close by the end of the year.

The cash-for-stock deal would pay EndoChoice stockholders $8 per share. On Monday, stock in the eight-year-old company closed at $4.22 per share.

For Boston Scientific, the deal is expected to break even in 2017 and become profitable on an adjusted-earnings basis thereafter.

EndoChoice sells devices for seeing and interacting with things inside the intestines, plus infection-control products and pathology services for treatment of a range of gastrointestinal conditions. The company has customers in about 2,500 gastrointestinal departments, representing a third of the U.S. market, securities filings say.

EndoChoice reported a $59.4 million loss on revenue of $72.3 million in 2015, compared with a $53.6 million loss on revenue of $61.4 million in the previous year. About 90 percent of its sales were in the U.S.

One of EndoChoice's bestselling products is the full spectrum endoscopy, or Fuse, colonoscope system, which has been shown in studies to enable doctors to find more lesions during exams.

"With respect to the Fuse colonoscope, Boston Scientific intends to evaluate strategic options, and expects to provide further clarity at or around the time of transaction closing," the company said in a statement.